Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Winlevi And Aimmune Excitement Will Be Short-Lived

Executive Summary

Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.

You may also be interested in...



Nestle, Bullish On Palforzia, To Buy Remainder Of Aimmune

Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.

Stockwatch: Is Mallinckrodt Deep Value Pharma?

The pandemic has affected generic pharmaceutical companies more than their branded brethren but accident-prone Mallinckrodt has been hit harder than most.

Stockwatch: The Fall, Rise And Challenges Of Seres' Microbiome Therapy

The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel